These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25753830)

  • 1. Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.
    Zhu L; Zhang Y; Yang J; Wang Y; Zhang J; Zhao Y; Dong W
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):395-402. PubMed ID: 25753830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.
    Zhu L; Yang J; Zhang Y; Wang Y; Zhang J; Zhao Y; Dong W
    Korean J Physiol Pharmacol; 2015 Mar; 19(2):99-104. PubMed ID: 25729270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers.
    Lee HK; DeVito V; Vercelli C; Tramuta C; Nebbia P; Re G; Kovalenko K; Giorgi M
    Res Vet Sci; 2017 Jun; 112():26-33. PubMed ID: 28113087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs.
    Yuan LG; Luo XY; Zhu LX; Wang R; Liu YH
    J Vet Pharmacol Ther; 2011 Jun; 34(3):224-31. PubMed ID: 20950354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetics of bisphenol A.
    Shin BS; Kim CH; Jun YS; Kim DH; Lee BM; Yoon CH; Park EH; Lee KC; Han SY; Park KL; Kim HS; Yoo SD
    J Toxicol Environ Health A; 2004 Dec; 67(23-24):1971-85. PubMed ID: 15513896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
    Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
    Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
    Gao ZW; Zhu YT; Yu MM; Zan B; Liu J; Zhang YF; Chen XY; Li XN; Zhong DF
    Acta Pharmacol Sin; 2015 Dec; 36(12):1528-36. PubMed ID: 26592518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of levofloxacin in non-lactating goats and evaluation of drug effects on resistance in coliform rectal flora.
    Vercelli C; Łebkowska-Wieruszewska B; Barbero R; Lisowski A; Re G; Giorgi M
    Res Vet Sci; 2020 Dec; 133():283-288. PubMed ID: 33039880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
    Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys.
    Aboubakr M; Uney K; Elmas M
    Br Poult Sci; 2014 Feb; 55(1):115-9. PubMed ID: 24735473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses.
    Liu D; Xu S; Xiao H; Wang Z; Mao N; Zhou J; Liu R; Huang Y
    J Pharm Pharmacol; 2014 Sep; 66(9):1215-21. PubMed ID: 24961375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans.
    Lin Z; Li M; Gehring R; Riviere JE
    J Pharm Sci; 2015 Jan; 104(1):233-43. PubMed ID: 25407474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
    Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
    Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
    Bouchene S; Marchand S; Couet W; Friberg LE; Gobin P; Lamarche I; Grégoire N; Björkman S; Karlsson MO
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):407-422. PubMed ID: 29665289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
    Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
    Laplanche R; Meno-Tetang GM; Kawai R
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.